For research and educational purposes only. Not medical advice.

Pemvidutide Reference

Educational, not medical advice reference for Pemvidutide: GLP-1, Fat Loss; regulatory status, evidence posture, source review, and schedule not…

Reference summary

The IMPACT Phase 2b MASH trial (Lancet 2025, PMID 41237796) reported 24-week MASH-resolution and fibrosis-biomarker endpoints in adults with biopsy-confirmed MASH treated with fixed once-weekly subcutaneous pemvidutide (1.2 mg or 1.8 mg, without titration) vs placebo; the sponsor separately reported 48-week topline in December 2025. Phase 2 obesity data have also been reported by the sponsor. Common adverse events were dose-dependent gastrointestinal consistent with the GLP-1 / glucagon class.

Regulatory and posture

Categories
GLP-1, Fat Loss
Aliases
ALT-801, GLP-1 / glucagon dual receptor agonist
Evidence posture
human - Phase 2 IMPACT MASH data are published, with 48-week data in December 2025; the Phase 3 PERFORMA MASH trial is planned to begin in the second half of 2026 (FDA Breakthrough Therapy designation for MASH). Pemvidutide remains investigational.
Regulatory status
Investigational. Pemvidutide is a GLP-1 / glucagon dual receptor agonist developed by Altimmune with Phase 2 programs in MASH and obesity; a Phase 3 PERFORMA MASH trial is planned to begin in the second half of 2026. There is no FDA-approved drug label.
Content review status
investigational verified

Selected public sources

Related tools